12 completed, 2 active not recruiting, 2 terminated. 8 Phase 3, 4 Phase 1, 3 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Active not recruiting 2, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow anagrelide: new trials by email Literature Review of anagrelide trials Research Report on anagrelide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Ropeginterferon alfa-2b, Anagrelide - Essential Thrombocythemia | Phase 3 | Active not recruiting | PharmaEssentia | 174 | 2020-08-25 | 2026-07-22 |
| Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants SPD422, Omeprazole - Healthy Volunteers | Phase 1 | Completed | Shire | 20 | 2019-02-26 | 2021-06-15 |
| Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) Ruxolitinib, Anagrelide, Placebo - MPN (Myeloproliferative Neoplasms) | Phase 2 | Terminated | Incyte Corporation | 12 | 2017-11-14 | 2021-11-19 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| Anagrelide Retard in Essential Thrombocythemia Anagrelide retard, Thromboreductin - Essential Thrombocythemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 106 | 2014-02-01 | 2015-07-29 |
| Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers Anagrelide 0.5 mg, Anagrelide 2.5 mg, Moxifloxacin - Healthy | Phase 1 | Completed | Shire | 60 | 2012-03-29 | 2021-06-09 |
| Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® Anagrelide hydrochloride - Essential Thrombocythemia (ET) | Completed | Shire | 47 | 2011-07-19 | 2021-07-30 | |
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) ruxolitinib tablets, Best Available Therapy (BAT) - Polycythemia Vera | Phase 3 | Completed | Incyte Corporation | 222 | 2010-10-27 | 2019-03-06 |
| Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia SPD422 (anagrelide hydrochloride) - Essential Thrombocythemia (ET) | Phase 3 | Completed | Shire | 41 | 2010-10-27 | 2021-06-09 |
| Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Anagrelide Hydrochloride - Essential Thrombocythemia (ET) | Phase 3 | Completed | Shire | 53 | 2010-10-27 | 2021-06-09 |
| The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) anagrelide hydrochloride - Essential Thrombocythaemia | Phase 2 | Completed | Shire | 24 | 2006-11-13 | 2021-06-29 |
| A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Anagrelide, Hydroxyurea - Thrombocythemia, Hemorrhagic | Phase 4 | Completed | Shire | 150 | 2006-01-13 | 2021-06-02 |
| Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg Anagrelide Hydrochloride Capsules 1 mg, Agrylin® Capsules 1 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 22 | 2003-01-01 | 2024-04-24 |
| Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg Anagrelide Hydrochloride Capsules 1 mg, Agrylin® Capsules 1 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 47 | 2003-01-01 | 2024-04-24 |
| Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Anagrelide, Hydroxyurea - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 2002-09-01 | 2010-10-06 |
Thrombocythemia, Essential (11) · Myeloproliferative Disorders (3) · Polycythemia Vera (1)
Shire (7) · AOP Orphan Pharmaceuticals AG (2) · Incyte Corporation (2) · Mylan Pharmaceuticals Inc (2) · French Innovative Leukemia Organisation (1) · Merck Sharp & Dohme LLC (1) · PharmaEssentia (1)
United States (7) · France (6) · Japan (5) · Hungary (4) · Italy (4) · Poland (4) · Canada (3) · China (3) · Germany (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Austria (2)
James Carlson, Pharm. D. (2) · Albert Assad, MD (1) · Craig Zimmerman, PhD (1) · Heinz Gisslinger, Prof., MD (1) · Mark Jones, MD (1) · Srdan Verstovsek, MD,PhD (1) · Toshiaki Sato, MD/PhD (1)
PMID 22943924, PMID 23315161, PMID 25160063, PMID 25629741, PMID 26028965, PMID 27102499, PMID 28193568, PMID 29396713, PMID 30121892, PMID 30368038, PMID 31982039, PMID 33123978, PMID 35924546, PMID 41193116, PMID 41890273
2004 (2), 2023 (1)